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ABBREVIATIONS AND NOMENCLATURE 
 
 
The nomenclature used in this report is recommended by the manufacturers of the 
experimental kits and reagents. Abbreviations are defined where they appear in the 
text. The following list shows the frequently used abbreviations in this report: 
 
Abbreviations  Complete nomenclature  
ATP    adenosine triphosphate   
DEPC    diethyl pyrocarbonate 
DNA    deoxyribonucleic acid 
GEPH    gephyrin 
Mo     molybdenum 
MoCo     molybdenum cofactor 
MOCS    molybdenum cofactor synthesis 
MPT    molybdopterin 
mRNA    messenger ribonucleic acid 
PCR    polymerase chain reaction 
Poly A+ RNA   polyadenylated ribonucleic acid 
ppm    parts per million 
RNA    ribonucleic acid 
RT-PCR   reverse transcription – polymerase chain reaction 
SDS    sodium dodecyl sulphate 
SO
2-
3     sulphite 
SSC    standard saline citrate 





Sulphite oxidase (EC 1.8.3.1) is a molybdopterin-containing enzyme that is 
ubiquitous in animals and physiologically catalyses the oxidation of sulphite to 
sulphate. The expression of the sulphite oxidase gene in human and rat tissues was 
investigated and it was found that the human liver, kidney, skeletal muscle, heart, 
placenta and brain showed substantial expression while thymus, spleen, peripheral 
blood leucocytes, colon, small intestine and lung showed little expression in 
humans. In rat, the liver, kidney, heart, brain and lung (but not skeletal muscle) 
revealed a hybridization signal with the strongest signal in the liver. The spleen 
and testis also showed little expression. Expression of sulphite oxidase gene was 
seen in all human brain regions examined (cerebellum, cerebral cortex, medulla, 
spinal cord, occipital pole, frontal lobe, amygdala, caudate nucleus, corpus 
callosum, hippocampus, thalamus, temporal lobe and putamen). The cerebral 
cortex showed the highest level of expression.  
 xi
1.  INTRODUCTION 
 
1.1 Sulphite oxidase 
Sulphite oxidase (EC 1.8.3.1), localizing exclusively in the mitochondrial 
intermembrane space (Ito, 1971; Wattiaux-De Coninck and Wattiaux, 1971 and 
Cohen et al, 1972), is a molybdopterin-containing enzyme that catalyses the 
oxidation of sulphite (SO
2-
3 ) to sulphate (SO
2-
4 ) (Figure 1). It is ubiquitous in animals 
and physiologically it catalyses the terminal step in the oxidative degradation of 
sulphur- containing amino acids: cysteine and methionine (Figure 2), 
 
 
          SO2-3  + H2O                          SO
2-






Figure 1. The chemical reaction catalysed by sulphite oxidase  
 
 
and membrane components such as the sulphatides. The enzyme is a homodimer of 
subunits of mass 52 kDa, which contains a small N-terminal cytochrome b5 type 
heme domain (10 kDa) and a large C-terminal molybdenum cofactor-binding 
domain (42 kDa) (Rajagopalan, 1980) that contains most of the residues involved in 
the dimerization interface (Kisker et al, 1997). The two domains are linked by a 
hinge region that is highly sensitive to trypsin cleavage (Johnson and Rajagopalan, 
1977). Oxidation of sulphite to sulphate occurs at the molybdenum center with the 










Figure 2. Metabolic pathway of sulphur amino acids to sulphite and sulphate. 
(Modified from Cooper, 1983 and Chan et al, 2002) Sulphur amino acids, 
methionine (an essential amino acid) and cysteine, enter the mammalian 
metabolic pathway either exogenously through dietary uptake or 
endogenously via the metabolic pathway of cysteine. They are then 
metabolised through a series of enzymatic reactions, generating sulphites as 
by-products. Sulphites, in quantities of about 1000 mg/day, are produced 








generated are transferred, one at a time, through the b5-type cytochrome to the 
physiological terminal electron acceptor cytochrome c on the mitochondrial inner 
membrane in a two-step reaction (Figure 3). The complete amino acid sequences of 
sulphite oxidase from chicken (Neame and Barber, 1989), rat (Garrett and 
Ragjagopalan, 1994) and human (Garrett et al, 1995) sources have been determined. 
The sequence identity among the eukaryotic sulphite oxidases is very high, with 
chicken and human enzymes sharing 68% identity, and rat and human enzymes 
sharing 88% identity. The X-ray crystal structure of sulphite oxidase from chicken 
liver has been determined at 1.9 Å resolution (Figure 4) (Kisker et al, 1997). 
In humans, the gene encoding the sulphite oxidase (SUOX) is located on 
chromosome 12, in the region of 12q13.2-12q13.3 (GenBank accession number 
AY056018). The SUOX gene spans approximately 2.4 kb with a 1 kb intron that 
occurs in proximity to the 5’ end of the coding region. A 466-amino acids human 
sulphite oxidase, encoded by a single exon (Lam et al, 2002), is synthesized with a 
22-residue leader sequence that directs it to the mitochondrial intermembrane space. 
Recently, the crystal structure of the oxidised human sulphite oxidase cytochrome b5 
domain has been determined at a resolution of 1.2 Å and has been refined to a 
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Figure 3. Schematic representation of sulphite oxidase in the mitochondrial 
intermembrane space. (Adapted from Johnson and Rajagopalan, 1977 and 
1979; Kisker et al, 1997 and Schindelin et al, 2001) Sulphite oxidase 
localises exclusively in the mitochondrial intermembrane space and is 
ubiquitous in eukaryotes. It is a homodimer with each subunit possessing 
one large molybdenum cofactor-binding domain and one small cytochrome 
b5 type heme domain. During the oxidation of sulphite to sulphate, the 
molybdenum center of sulphite oxidase is reduced from the VI to the IV 
valence state. Two electrons are subsequently transferred through the b5-
type cytochrome to the physiological terminal electron acceptor cytochrome 
c on the mitochondrial inner membrane in a two-step reaction. The reaction 
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Figure 4. Structure of chicken sulphite oxidase. (Kisker et al, 1997) The two 
sulphite oxidase subunits are asymmetrically represented in an overall 
dimensions of 120 x 55 x 70 Å. The chicken sulphite oxidase is a homodimer 
with a molecular mass of approximately 110 kDa and each monomer is 
divided into three domains. Domain I (red) harbors the cytochrome b5 heme 
(~10 kDa) whereas domains II and III (combined molecular weight ~42 kDa) 
consist of the molybdenum cofactor domain (yellow) and an immunoglobulin-
like domain which is responsible for dimerization (green). The N-terminal 
domain is drawn in red, the MoCo domain in yellow and the C-terminal 
domain in green. The MoCo and the heme are shown in ball-and-stick 
representation with the Fe atom in purple and the Mo atom in green. The 
gray dotted lines connect the metal centers of the cofactors and indicate the 
distances between the Mo and Fe within the monomer and the Mo-Mo 






1.2 Sulphite oxidase deficiency 
1.2.1 Molybdenum cofactor deficiency 
A deficiency of sulphite oxidase in humans leads to progressive cerebral 
degeneration, major neurological abnormalities, dislocated ocular lenses, mental 
retardation, severe seizures and early death, usually between two and six years of 
age (Johnson and Wadman, 1995 and Lyon et al, 1996). Sulphite oxidase deficiency 
is a rare autosomal-recessive condition with asymptomatic heterozygous carrier. To 
date, approximately 80 cases of sulphite oxidase deficiency have been documented 
worldwide, two of which were reported in Singapore (Goh and Lim, 1997). Sulphite 
oxidase deficiency can occur for either two reasons (Johnson and Wadman, 1995). 
The first is a defect in the synthesis of molybdenum cofactor, which also involves 
xanthine dehydrogenase and aldehyde oxidase, the other two molybdenum cofactor-
containing enzymes. Molybdenum cofactor deficiency is an autosomal recessive 
trait (MIM, 252150 and 252160; http:www.ncbi.nlm.nih.gov).  It is a unique pterin 
compound that possesses a single molybdenum ion (Figure 5). The biosynthesis of 
this molybdenum cofactor in humans is thought to proceed in three major steps: [1] 
the formation of precursor Z from GTP (guanosine triphosphate) (Figure 6), [2] the 
conversion of the precursor Z to molybdopterin (MPT) (Figure 7), and [3] the 
incorporation of molybdenum into MPT by gephyrin, thus forming MoCo (Figure 8) 
(Reiss 2000). These three steps account for the molecular basis of three existing 
MoCo deficiency, namely the complementation group A (MIM 252150) and B 
(MIM 252160) that is defective in mocs1 and mocs2 respectively, and mutations in 
















Figure 5. Structure of the molybdenum cofactor. The structure of the organic 
component of the molybdenum cofactor (MoCo) in tricyclic form is observed 
in all crystal structures of enzymes containing this cofactor. This tricyclic 
pyranopterin contains a cis-dithiolene group in its pyran ring. Together with 
the molybdenum ion, it is commonly referred as molybdenum cofactor. 










Figure 6. Conversion of a guanosine derivative to precursor Z by mocs1 
(molybdenum cofactor syntheis) gene products. The unusual biscistronic 
nature of mocs1 allows two different consecutive open reading frames 
(OFRs) in a single transcript to encode for two enzymes MOCS1A and 
MOCS1B to catalyse the synthesis of precursor Z, an oxygen-sensitive 6-
alkyl pterin with a cyclic phosphate, from a guanosine derivative, that is most 
probably GTP (guanosine triphosphate). (Adapted from Hanzelmann et al, 





































Figure 7. The conversion of precursor Z into molybdopterin (MPT). The 
conversion of precursor Z into MPT is catalysed by MPT synthase and MPT 
synthase sulphur transferase. MPT synthase is a heterodimeric enzyme that 
comprises a small MOCS2A subunit and a large MOCS2B subunit. These 
two subunits, which are translated by leaky scanning, are encoded by a 
single transcript with two overlapping ORFs of mocs2. MPT synthase 
sulphur transferase activates MPT synthase by sulphation. Sulphated MPT 
synthase then transfers two sulphur atoms to precursor Z. MPT synthase 
















Figure 8. The incorporation of molybdenum into MPT by gephyrin. Gephyrin 
is thought to catalyse the insertion of molybdenum ions into molybdopterin, 
presumably by its high affinity in binding molybdopterin and its structural 
capability in facilitating a coordinated and efficient transfer of molybdenum 
ions to molybdopterin. 
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Briefly, the biosynthesis of precursor Z (a sulphur-free pterin compound) is  
catalysed by the enzymatic activities of MOCS1A and MOCS1B. This biosynthetic 
process utilises a guanosine-X-derivative, which is most probably GTP, as the initial 
precursor of the pterin ring (Wuebbens et al, 1995 and Rieder et al, 1998). Precursor 
Z is then converted to MPT by heterodimeric MPT synthase (encoded by mocs2) 
and MOCS3, the MPT synthase sulphur transferase that catalyses the incorporation 
of two sulphur atoms into precursor Z.  
Finally, molybdenum incorporation requires the function of a neuroprotein, 
gephyrin, which is a putative cofactor carrier protein and a molybdate transport 
system governing molybdate uptake (Feng et al, 1998; Stallmeyer et al, 1999; 
Ramming et al, 2000; Grosskreutz et al, 2003; David-Watine, 2001; Reiss et al, 
2001). A schematic representation of the involved human genes is shown in Figure 8 









Table 1. Genes involved in molybdenum cofactor deficiency and their 
chromosomal localizations. 
Gene Chromosomal localization References 
mocs1 Chromosome 6p21.3 Shalata et al, 1998; Reiss, 2000 
mocs2 Chromosome 5q11 Reiss, 2000 








Figure 9. The roles of human genes involved in the molybdenum cofactor 
biosynthesis pathway (Reiss, 2000). Biosynthesis of molybdenum cofactor 
requires the products of at least four different genes, namely mocs1, mocs2, 
mocs3 and geph. Both mocs1 and mocs2 possess a bicistronic architecture. 
This means that each gene encodes two polypeptides in different open 
reading frames. MOCS1A and MOCS1B are the protein products expressed 
from different mRNAs generated by alternative splicing whereas MOCS2A 
and MOCS2B are the protein products expressed by independent translation 
of a biscistronic mRNA. While MOCS1A and MOCS1B are required for the 
formation of precursor Z from GTP, MOCS2A and MOCS2B convert the 
precursor to molybdopterin. For classification, patients in complementation 
group A are deficient in MOCS1A and MOCS1B while patients in 
complementation group B are lacking of MOCS2A and MOCS2B. In order to 
be functional, MOCS2A and MOCS2B must be activated by a 
sulphotransferase, which is the product of the intronless gene mocs3. To 
date, no disease-causing mutations have been found in mocs3. Geph 
encodes the gephyrin protein, which is necessary for insertion of 








1.2.2 Isolated sulphite oxidase deficiency 
The second reason for the occurrence of sulphite oxidase deficiency in 
humans is a specific sulphite oxidase defect arising from mutations in the SUOX 
gene located on chromosome 12. Isolated sulphite oxidase deficiency (MIM, 
272300) is a rare autosomal recessive disease with a characteristic biochemical 
feature of elevated urinary excretion of sulphur metabolites, including sulphite, 
thiosulphate, and S-sulphocysteine, as well as neurotoxicity and early death. 
 
 
1.3 Prenatal diagnosis of isolated sulphite oxidase deficiency 
The deficiency of sulphite oxidase can be diagnosed prenatally by several 
methods (Johnson 2003). One common way is to detect the sulphite oxidase activity 
in cultured amniocytes (Gray et al, 1990) and in uncultured chorionic villus samples  
(CVS) (Johnson et al, 1991). As the levels of sulphite oxidase in amniocytes are 
very low, culturing of large amount of cells is necessary. Yet, it yields qualitative 
rather than quantitative results (Johnson et al, 1991). Conversely, CVS assays allow 
faster quantitative results at an early stage of the pregnancy (10 to 11 weeks of 
gestation compared to 16 to 18 weeks of gestation for amniocentesis) and direct 
assay on biopsy samples, making it a better choice of investigation. Measurements 
of the levels of S-sulphocysteine and sulphite in amniotic fluid also provide reliable 
indicators. S-sulphocysteine, which is formed by direct reaction of sulphite with 
cysteine (Johnson and Wadman, 1995), can be easily detected by ion 
chromatography (Johnson and Rajagopalan, 1995) or mass spectrometry (Kishikawa 
et al, 2000).    
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 DNA-based prenatal diagnosis has been described to be informative and be 
able to provide an accurate determination of carrier status (Lam et al, 2002). By 
large, it is likely to identify families in which the affected gene and specific defect 
have been characterised.   
 Of interest, the differentiation between isolated sulphite oxidase deficiency 
and molybdenum cofactor deficiency in infants is based on biochemical findings – 
low plasma uric acid, and high urine xanthine and hypoxanthine are found in 
molybdenum cofactor deficiency, while normal plasma uric acid, urine xanthine and 
hypoxanthine levels are detected in isolated sulphite oxidase deficiency (van der 
Klei-van Moorsel et al, 1991). Of the two variants, isolated sulphite oxidase 
deficiency appears to be much less common (Edwards et al, 1999). To date, no 
effective therapeutic intervention is available (Johnson, 2003). 
 
1.4 Sulphites 
The dramatic effects of sulphite oxidase deficiency strongly suggest that 
removal of SO
2-
3  is essential, especially in the brain. Yet, sulphites (widely defined as 
the sulphiting agents, sulphur dioxide gas, metabisulphite, bisulphite and sulphite, 
see Table 2) are often encountered in the environment (Walker, 1985 and Lester, 
1995). For centuries, sulphites in various forms have been used regularly and 
extensively for the preparation, storage and distribution of food. Their widespread 
use evidently demonstrates their effectiveness as antimicrobial and fungistatic 
agents, as inhibitors of enzymatic and non-enzymatic browning reactions, as 
antioxidants, and as blanching agents (Walker, 1985; Taylor et al, 1997 and 
Leclercq et al, 2000). Furthermore, sulphites remain on the U.S. Food and Drug 
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Administration GRAS (generally recognised as safe) list (assessable at 
http://vm.cfsan.fda.gov/~dms/eafus.html), although some sensitive individuals 
exhibit adverse reactions to sulphite residues in foods (Walker, 1985; Simon, 1986; 
Gunnison and Jacobsen, 1987; Lester, 1995; Taylor et al, 1997). It is postulated that 
some sulphite-sensitive asthmatics might have reduced levels of sulphite oxidase 
(Simon 1986). In addition, contact with sulphites may also result from the inhalation 
of sulphur dioxide (Table 3), which is one of the most frequently occurring air 
pollutants (WHO, 2000) or the ingestion of foods and drugs treated with sulphiting 
agents (Taylor et al, 1997); examples being meat production and white wines. Given 
the ubiquity of sulphites in our environment and the physiological importance of 








Table 2. Sources of sulphites 











Table 3. The overall annual average sulphur dioxide levels in Singapore. 







Source: Strategic Planning & Research Department, Ministry of Environment, 
Singapore 
 
In Singapore, daily sulphur dioxide level can be assessed at the National 





1.5 Aim of this study 
Studies of sulphite oxidase activity distribution using cytochrome c reduction 
methodology in animal tissues have been reported. Generally, high sulphite oxidase 
activity is observed in liver, kidney and heart and low activity is indicated in brain, 
spleen and testis (Cabre et al, 1990). In this study, the expression of human and rat 
sulphite oxidase genes was examined using Northern blot analysis. In addition, this 
study also aims to elucidate the regulatory mechanisms of sulphite oxidase gene 
expression. It is in the hope of understanding the regulatory mechanisms of gene 







2.1 Chemical and reagents 
All chemicals and reagents were obtained from the highest grade available 
from Sigma (St. Louis, MO), unless otherwise stated. Reagents for total RNA 
purification were from Invitrogen (Carlsbad, CA), for Poly A+ RNA purification 
from Qiagen (Hilden, Germany), for RT-PCR amplication from Promega (Madison, 
WI), for DNA sequencing from PE Biosystems (Foster City, CA), and for 





2.2 Cell lines and culture 
HepG2 (transformed human liver cell), MDCKII (canine kidney cell) and 
Neural 2A (mouse neuroblastoma) and human foetal liver cell lines were kindly 
provided by Professor Wong Kim Ping from the Department of Biochemistry in the 
National University of Singapore. All cell lines were cultured in Dulbecco’s 
Modified Eagle Medium (DMEM) containing 10% foetal bovine serum, 100 U/ml 
penicillin G, 100 µg/ml streptomycin sulphate and 0.25 µg/ml amphotericin B 
(Gibco, Grand Island, NY). All cell lines were grown in a 37°C humidified 




3. METHODS  
 
3.1 Differential expression profiles of sulphite oxidase in rat and human 
tissues  
3.1.1 Assay of sulphite oxidase activity using cytochrome c reduction 
methodology 
The activity of sulphite oxidase can be assayed in several ways. In brief, 
methodologies relying on the reduction of cytochrome c, the reduction of 
ferricyanide, the direct spectrophotometric assay of sulphite oxidation, the oxygen 
consumption rate, the reduction of 2,6-dichloroindophenol, the reduction of 
methylene blue and the depletion of sulphite have been described (Cohen and 
Fridovich, 1971). In this study, cytochrome c reduction methodology (Johnson et al, 
1991) was selected to assay sulphite oxidase activity as it is most commonly 
described (Johnson, 2003).  
Flash-frozen tissues were weighed and homogenised with a Dounce glass 
homogeniser at 4°C in five volumes of 0.01M Tris-HCl, pH 8.5 containing 0.01mM 
EDTA. For every 1 ml of homogenate, 50 µl of 1% (w/v) sodium deoxycholate and 
10 µl of 50mM sodium cyanide were added. The samples were then centrifuged at 
12 000 × g for 3 min at 4°C.  1 ml of the supernatant was desalted on PD-10 gel 
filtration column (Pharmacia, Erlangen, Germany) equilibrated with assay buffer 
(0.1M Tris-HCl, pH 8.5, 0.1mM EDTA). Using 1.5ml of assay buffer to wash and 
2ml of assay buffer to elute, aliquots of 200 - 400µl of the eluate were assayed for 
sulphite oxidase activity at 25°C by monitoring the reduction of cytochrome c at 
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550nm. 50µl of 1mM cytochrome c (from Horse heart, dissolved in assay buffer), 
extract aliquot and assay buffer to a final volume of 1ml were added to an assay 
cuvette. After recording the blank rate of cytochrome c reduction for 4-5min, 10µl 
of 50mM sodium sulphite was added and the increase in absorbance at 550nm was 
recorded again for the same period of time (Figure 10 presents a graphical view of 
the principle behind the assay). Protein concentration was determined according to 
the manufacturer’s instructions using the Bradford-assay-kit (BioRad, Hercules, 
CA). Sulphite oxidase activity was calculated as the difference between the rate 
observed in the presence of sulphite and the blank rate. A unit of sulphite oxidase 
activity is defined as enzyme sufficient to produce an increase of 1.0 absorbance unit 
at 550nm per min at 25°C. Activity is expressed as units per milligram tissue (wet 
weight). 
 19
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Figure 10. A graphical view of the assay of sulphite oxidase activity using 
cytochrome c reduction methodology. The graph depicts an experiment in 
which clear homogenate from rat tissues was assayed. When a mixture of 
Tris buffer and cytochrome c was added to a cuvette with a 1.0-cm ligh path, 
there was essentially no change in optical density at 550 nm, even when 
sulphite was added. The reaction was started by addition of the clear 
homogenate which contained the sulphite oxidase enzyme. An immediate 
and linear increase in optical density at 550 nm was observed and this 
continued until the attainment of a plateau value corresponding to complete 




3.1.2 Northern blot analysis 
Multiple tissue Northern (MTN™) blots containing poly A+ RNA from 
various tissues were obtained from Clontech Laboratories Inc. (Palo Alto, CA). The 
human and rat poly A+ RNA samples were from different donors and were free of 
disease as reported in the product analysis certificate. Human 12-Lane MTN™ Blot, 
Human Brain MTN™ Blot II, Human Brain MTN™ Blot IV and Rat MTN™ Blot 
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were used to study the expression of the sulphite oxidase. A biotinylated human or 
rat sulphite oxidase DNA probe was prepared by random priming labeling procedure 
(Feinberg and Volgelstein, 1983 and 1984) using North2South™ Biotin Random 
Prime kit (Pierce, Rockford, IL) according to the manufacturer’s instructions. 
Briefly, about 100 ng of linear DNA in a total volume of 24 µl was mixed with 10 µl 
of 5X heptanucleotide mix and boiled for 5 min to denature the DNA template. 
Following denaturation, it was immediately frozen in dry ice/ethanol bath for 5 min. 
After thawing on ice, 10 µl of 5X dNTP (0.8mM dATP, 0.8mM dTTP, 0.8mM 
dGTP, dCTP, 0.5mM Biotin-N4-dCTP), 5 µl of 10X reaction buffer and 1 µl of 
DNA polymerase, Klenow fragment (3’-5’ exo-) (10U/µl) were added to the sample 
and incubated for 1 hr at 37°C. The reaction was terminated by the addition of 2 µl 
of 500 mM EDTA, pH 8.0. Removal of unincorporated nucleotides was done using 
GFX™ PCR DNA and Gel Band Purification kit (Amersham, Piscataway, NJ), 
following exactly the manufacturer’s protocols.    
The templates for preparing biotinylated DNA probe were generated by RT-
PCR amplification, using Access RT-PCR System (Promega, Madison, WI) from rat 
liver poly A+ or HepG2 cell line poly A+. Primers for the rat sulphite oxidase probe 
corresponded to nucleotides 378-397 (forward) and nucleotides 1181-1200 (reverse, 
RT-PCR product of 823 bp) of the rat sulphite oxidase mRNA sequence (GenBank 
accession no. NM_031127). Primers for the human sulphite oxidase probe 
corresponded to nucleotides 1377-1397 (forward) and nucleotides 2180-2199 
(reverse, RT-PCR product of 823 bp) of the human sulphite oxidase mRNA 
sequence (GenBank accession no. NM_000456).  The exact sequences of the primer 
and the RT-PCR cycling profile are shown in Table 4. In short, RT-PCR 
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amplifications consisted of 50-µl reaction mixtures containing 1µM of each 
oligonucleotide primer, 200 µM each of the four dNTPs, 1 µM MgSO4, 5 units of 
AMV Reverse Transcriptase, 5 units of Tfl DNA polymerase and 0.5 µg of poly A+. 
Reaction mixtures were overlaid with 1 drop of nuclease-free mineral oil to prevent 
condensation and evaporation, and subjected to the following amplification 
conditions:  an initial cycle of 45 min at 48°C for reverse transcription and 2 min at 
94°C for AMV Reverse Transcriptase inactivation and RNA/cDNA/primer 
denaturation, followed by 40 cycles of PCR. The PCR step comprises 30 s of 
denaturation at 94°C, 1.5 min of annealing at 60°C for and 2 min of extension at 
68°C, and 1 final extension cycle of 7 min at 68°C. Reactions were performed in a 
Biometra® Tpersonal thermal cycler.  
After PCR cycling, the amplified PCR products were analyzed on 1% 
agarose gels. A fragment of 823bp was obtained. Nucleotide sequences were 
determined by the dideoxy chain termination method using BigDyeDeoxy 
Terminator Cycle sequencing kit (PE Biosystems, Foster City, CA) according to the 
manufacturer’s instructions.  β-actin or glyceraldehyde-3 phosphate dehydrogenase 
(GAPDH) was used as a housekeeping gene and their cDNA were obtained from 
Clontech Laboratories Inc. (Palo Alto, CA). Poly A+ RNA were isolated from rat 
liver and HepG2 cell line using Oligotex Direct mRNA kit (Qiagen, Hilden, 
Germany).   
Hybridization and washing were performed according to the manufacturer’s 
recommendations using North2South™ Chemiluminescent Nucleic Acid 
Hybridization and Detection kit (Pierce, Rockford, IL).  Autoradiographs were 
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exposed for 10-600 s on CL-Xposure™ Xray film (Pierce, Rockford, IL) or BioMax 





Table 4 . Primers for DNA amplification by RT-PCR. 
Primer Sequence (5’Æ3’) Location 
PCR product size 
(bp) 
RatSO3 CCTGATTCTACAGTCGTCCC 378-397# 823 
RatSO5 CCCCTCCCTTGGAGGCCTCT 1181-1200#  
HuSO3 ACGCCATGCCCAGGCCTTCC 1377-1397@ 823 
HuSO5 CACCCGGAACCATCTGCCTGT 2180-2199@  
 
Cycling profile   
1 cycle  48°C for 45 min reverse transcription 
1 cycle  94°C for 2 min AMV RT inactivation and 
RNA/cDNA/primer denaturation 
 
40 cycles  94°C for 30 sec 
60°C for 1 min 




1 cycle  68°C for 7 min final extension 
1 cycle  4°C to soak soak 
 
#GenBank accession no. NM_031127 
 






3.2 To investigate the possibility of sulphite oxidase being transcriptionally 
regulated 
3.2.1 Effect of high protein diet on Sprague Dawley rats 
10 male Sprague-Dawley rats, each weighing 50 – 60g, were purchased from 
the Laboratory Animals Centre at the National University of Singapore and were 
randomly assigned to 2 diet groups of 5 animals each. Each diet group was housed 
in a stainless steel cage in a room of ambient temperature at 22 ± 2°C. The rats were 
given deionised water and diet ad libitum for 2 weeks.  For the control, the diet 
contained 18.9% protein, 5.2% fat, 5% fibre and 0.5mg Molybdenum/kg (Glen 
Forrest Stockfeeders, Australia). For the test diet, the diet contained 50.05% protein, 
5.48% fat, 0.265% fibre and 1.0mg Molybdenum/kg (Harlan Teklad, US). The 
formula details of both diets are shown in Table 5. At the end of the 2-week feeding 
period, the rats were anaesthetised in a chamber filled with CO2 and killed by 
cervical dislocation. Liver, kidney, stomach, intestine and heart were excised, 





















Table 5. Formula of the diets used. 
 Control diet 
Glen Forrest Stockfeeders, 
Australia 
Test diet 
Harlan Teklan,  
United States 
   
Protein 18.9% 50.05% 
Fat 5.2% 5.48% 
Crude Fibre 5% 0.265% 
Molybdenum 0.5 mg/kg 1.0 mg/kg 
   
Digestible 
energy 
3.46 kcal/g 3.76 kcal/g 
 
 
3.2.2 Effect of Molybdenum supplement, sodium sulphite and sodium 
tungstate administration on Sprague Dawley rats  
36 Sprague-Dawley rats, each weighing 50 – 60g, were purchased from 
Laboratory Animals Centre at the National University of Singapore and were 
randomly assigned to one of the five different experimental groups (Table 6). One of 
these experimental groups was designated as the control group that presumably 
possessed a normal level of hepatic sulphite oxidase activity while the remaining 
three were designated as treatment groups. All groups were given normal diet ad 
libitum provided by Glen Forrest Stockfeeders, Australia and were housed in a 
stainless steel cage in a room of ambient temperature at 22 ± 2°C.  All drinking 
solutions were made up in deionised water. Fresh 2M sodium sulphite (Fluka, 
Buchs, Switzerland) solutions were prepared daily to minimise decreases in sulphite 
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concentration due to auto-oxidation. Tungsten as the sodium salt was orally 
administered to the rats in an aqueous solutions of 500 ppm and 12 000 ppm 
whereas 2000 ppm of molybdate, prepared from sodium molybdate dihydrate 
(Merck, Darmstadt, Germany) was given likewise orally. All the solutions were 
offered to the rats ad libitum, in bottles for 5 consecutive weeks, except for 

















Diet Drinking-water supplementation 
W 15 Control Normal Normal#  None 
S 6 Treatment To be tested Normal 2M sodium sulphite  
T5 3 Treatment Deficient Normal 500 ppm tungstate 
T12 6 Treatment Deficient Normal 500 ppm tungstate for initial 
one week, followed by 
12 000 ppm tungstate for 
four week 
 
M 6 Treatment To be tested Normal 2 000 ppm molybdate 
 






3.2.3 Selection of cell lines 
For the selection of a suitable cell line to depict the dose-effect relationship, 
various cell lines, namely HepG2, MDCKII, Neural 2A and human foetal liver cell 
lines were used. All cell lines were cultured to confluence before poly A+ RNA 
isolation using Oligotex Direct mRNA kit (Qiagen, Hilden, Germany). 
 
3.2.4 Effect of sodium sulphite and sodium molybdate on HepG2 cell line 
 
HepG2 cell line was exposed to either 5mM of sodium sulphite or 5mM of 
sodium molybdate for 1 and 4 hours. For experimental control, no sodium sulphite 
or sodium molybdate was added during the 1-hr or 4-hr incubation. After incubation, 
the cells were harvested and poly A+ RNA was extracted for Northern blot analysis. 
Each experiment was performed at least twice. 
 
 
3.2.5 Northern blot analysis 
 
Total RNA was extracted from various rat tissues using Trizol reagent 
according to the manufacturer’s protocol (Invitrogen, Carlsbad, CA). Poly A+ RNA 
was isolated using Oligotex Direct mRNA kit (Qiagen, Hilden, Germany) from 
HepG2, MDCK and Neural 2A cells lines. RNA was quantified by measuring the 
absorbance at 260 nm in a spectrophotometer. To ensure significance, only readings 
greater than 0.15 units were accepted. Readings below 0.15 units were regarded as 
background. An absorbance of 1 unit at 260 nm corresponds to 40µg of RNA per 
ml. 40 µg of RNA or 20 µg of poly A+ RNA were dissolved in 5 volumes of loading 
buffer (62.5% (v/v) deionised formamide, 1.14 M formaldehyde, 50 mM MOPS, 
1.25 mM EDTA, pH 8.3, 12.5 mM sodium acetate, 200 µl/ml bromophenol blue, 
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200 µg/ml xylene cyanol). Just before loading onto 1.2% denaturing agarose gels 
containing 0.369 M formaldehyde, the samples and the 0.28-6.58kb RNA marker 
(Promega, Madison, WI) were heated for 10 min at 65°C followed by chilling on ice 
for 5 min and the gels were pre-run at 80 V for 10 min. The RNA samples were 
resolved at 80 V for 140 min.  After electrophoresis, the gels were sliced in pieces 
for different treatments. Gels containing the RNA marker were stained in 100 ml of 
a 5 µg/ml ethidium bromide solution for 2 min, followed by destaining in distilled 
water for 5 to 15 min. The ethidium bromide-stained gels were then viewed under an 
UV transilluminator and pictured along side with a fluorescent ruler for molecular 
weight sizing of the adjacent northern blot.  As for gels containing the RNA 
samples, they were first equilibrated in 50 mM NaOH solution for exactly 10 min. 
RNA was then transferred from the gels onto the positively-charged nylon 
membrane (Hybond N+, Amersham) for 2.5 hrs using a downward alkaline transfer 
setup as described by Ingelbrecht et al (1998) (Figure 11). Briefly, the membrane, 
the three 3-MM filter paper (Whatman International, Maidstone, England, UK) 
immediately below the membrane and the two on top of the gel, and the blotting 
wick were pre-soaked in 50 mM NaOH which was the transfer solution used in the 
transfer setup. After 2.5 hrs of blotting, the membrane was briefly neutralised in 
DEPC-treated 2X SSC buffer (3 M NaCl, 0.3 M sodium citrate, pH 7.0), air-dried 
overnight between 2 filter papers and stored at room temperature until further use. 
For Northern analysis, the blot was hybridised with biotinylated rat or human 
sulphite oxidase probe using North2South™ Chemiluminescent Nucleic Acid 
Hybridization and Detection kit (Pierce, Rockford, IL), according to the 
manufacturer’s recommendations. To check for RNA integrity and to correct for 
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differences in sample loading, the filter was rehybridised with a biotinylated β-actin 
probe or a biotinylated GAPDH probe after stripping in 0.1% SDS solution at 95°C 
for 10 min. Autoradiographs were exposed for 10-600 s on CL-Xposure™ X-ray 





Figure 11. Downward alkaline transfer of RNA. The figure above shows a 
schematic representation of the downward transfer setup. A sheet of pre-
soaked Hybond N+ positively-charged nylon membrane was positioned on 
top of the three pre-soaked Whatman 3MM filter paper lying just above a 
stack of paper towels about 5 cm thick. The formaldehyde-agarose gel was 
then put on the membrane, followed by two sheets of pre-soaked Whatman 
3MM filter paper. Paper towels around the gel were covered with plastic 
wrap to prevent short-circuit of water movement. A long wet blotting strip 
acting as a wick that attracted transfer solution (0.05 M NaOH) from 
containers on either side was placed over the buildup. A light plastic cover 
was placed on top of the setup to prevent evaporation. After each layer was 
put in place, air bubbles were carefully removed by rolling a glass rod over. 
Transfer was completed within 2.5 hrs. All pre-soaking was done using the 




4.1 Studies of sulphite oxidase activity distribution in rat using cytochrome 
c reduction methodology  
To re-examine the distribution of sulphite oxidase activity in rat tissues, three 
rats were sacrificed and their tissues were assayed for sulphite oxidase activity as 




Table 7. Occurrence of sulphite oxidase activity in Sprague-Dawley rats  
Tissue n Sulphite oxidase activity, units/mg 
Liver  3 0.976 ± 0.020 
Kidney  3 0.362 ± 0.004 
Heart  3 0.179 ± 0.024 
Intestine  3 0.020 ± 0.005 
 
A unit of sulphite oxidase activity is defined as enzyme sufficient to produce an 
increase of 1.0 absorbance unit at 550nm per min at 25°C. Activity is expressed as 
units per milligram tissue (wet weight). Data shown above are the mean values of 







4.2 Expression & tissue distribution of sulphite oxidase gene 
4.2.1 Human tissues 
The expression of sulphite oxidase gene was examined using Northern blot 
analysis (Table 8). As shown in Figure 12A and B, the hybridization signal with a 
size of approximately 2.4 kb occurred in some human tissues including the liver, 
kidney, skeletal muscle, heart, placenta, brain, thymus and spleen. Peripheral 
blood leucocyte, colon, small intestine and lung showed little expression.  
Increased expression in the liver coincides with high sulphite oxidase activity in 
this organ (Gunnison et al, 1977; Tejnorova, 1978; Beck-Speier et al, 1985 and 
Cabre et al, 1990). The differential expression of sulphite oxidase gene in various 
human brain regions was also examined (Figure 13A - E). As two different 
commercially available types of blot were used the expression level cannot be 
compared across all brain parts. From the first type of blot, a low level of 
expression was found in all brain regions, namely, cerebellum, cerebral cortex, 
medulla, spinal cord, occipital pole, frontal lobe, temporal lobe and putamen. 
Among these sites, the cerebral cortex shows the highest level of expression on 3 
separate blots (Figure 13A - C). On the other blots (Figure 13D and E) a generally 
low expression level was seen in all brain regions, namely, amygdala, caudate 







Table 8. An overview of the distribution of SUOX gene expression in 
mammalian tissues. 
Mammal Tissue SUOX expression 
Human Brain Present 
  Cerebellum Present 
  Cerebral cortex Present; High 
  Medulla  Present 
  Spinal cord Present 
  Occipital pole Present 
  Frontal pole Present 
  Temporal lobe Present 
  Putamen Present 
  Amygdala Present 
  Caudate nucleus Present 
  Corpus callosum Present 
  Hippocampus Present 
  Thalamus Present 
 Heart Present; High 
 Skeletal muscle Present; High  
 Colon Present; Low 
 Thymus Present 
 Spleen Present 
 Kidney Present; High 
 Liver Present; High 
 Small intestine Present; Low 
 Placenta Present 
 Lung Present; Low 
 Peripheral blood leucocyte Present; Low 
   
Sprague-Dawley rats Brain Present 
 Heart Present 
 Spleen Present 
 Lung Present 
 Liver Present; High 
 Skeletal muscle Absent 
 Kidney Present 






4.2.2 Rat tissues 
 Figure 14A and B show the expression pattern of sulphite oxidase gene in rat 
tissues. The liver, kidney, heart, brain and lung revealed a hybridization signal with 
a size of about 1.8 kb. As with human sulphite oxidase gene expression, the 
strongest signal was noted in the liver and there was substantial expression in the 



































































































































































Figure 12. Tissue expression of sulphite oxidase gene. A and B shows the 
Northern blot analysis of human sulphite oxidase gene expression in tissues. 
A hybridization signal (approximately 2.4 kb) occurred in most tissues in 
Human 12-Lane MTN™ Blot. Probing with β-actin as a control which results 
in bands at 2.0 kb and 1.8 kb respectively is shown at the bottom.  Results of 













































































































































































































































































































































Figure 13. Northern blot analysis of human sulphite oxidase gene expression in 
human brain parts.  A hybridization signal of approximately 2.4 kb occurred 
in all brain parts in Human Brain MTN™ Blot II (A, B and C) and Human 
Brain MTN™ Blot IV (D and E).  Probing with β-actin as a control which 
results in band at 2.0 is shown at the bottom. Signal detection with sulphite 
oxidase probe required a prolonged exposure compared with the β-actin 
control, which is responsible for the higher background. This indicates a low 
abundance. Results of three different blots for Human Brain MTN™ Blot II 
(A, B and C) and two different blots for Human Brain MTN™ Blot IV (D and 








































































































    














Figure 14. Tissue expression of sulphite oxidase gene.  A and B show the 
Northern blot analysis of various rat tissues with a sulphite oxidase probe.  
Probing with β-actin as a control which results in bands at 2.0 kb and 1.8 kb 
respectively is shown at the bottom. A hybridization signal (approximately 
1.8 kb) occurred in most tissues in Rat MTN™ Blot. Results of two different 
blots are shown. 
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4.3 Expression of rat sulphite oxidase gene under experimental conditions 
Previous study (Amy, 1988) demonstrated that rats fed with diets high in 
casein had a higher hepatic sulphite oxidase activity. This finding suggests that the 
SUOX gene could likely be induceable. In view of this, various experimental 
procedures were set up to elucidate the likelihood of the SUOX gene is under 
transcriptional regulation. 
 
4.3.1 Effect of high protein diet on Sprague Dawley rats  
To determine the effect of high protein diet on the SUOX gene expression in 
Sprague Dawley rats, the high casein diet (Amy, 1988) was repeated with 
modification in this study. Briefly, 50% protein diet (574.8 g/kg high protein casein 
and 131.5 g/kg sucrose) supplemented with 1 mg of Mo/kg, as compared with 50% 
casein diet (500 g/kg casein and 343 g/kg sucrose; Amy, 1988) was used in this 
study.  
Consistent with previous observations, the sulphite oxidase activities in liver 
and heart are higher in treated rats (Table 9), achieving an approximately two-fold 
induction. On the other hand, the northern blot analysis shows only little increase in 








Table 9. Higher sulphite oxidase activity in treated Sprague-Dawley rats.  
Sulphite oxidase activity, units/mg 
Tissue 
Control diet High protein diet 
Liver (n=5) 0.976 ± 0.020 1.684 ± 0.026 
Kidney (n=5) 0.536 ± 0.047 0.954 ± 0.077 
Heart (n=5) 0.179 ± 0.024 0.277 ± 0.008 
 
A unit of sulphite oxidase activity is defined as enzyme sufficient to produce an 
increase of 1.0 absorbance unit at 550nm per min at 25°C. Activity is expressed as 
units per milligram tissue (wet weight). Data shown above are the mean values of 























































Figure 15. Expression of rat sulphite oxidase gene in treated tissues. Northern 
blot analysis of various tissues from rats consuming high protein diet (S) and normal 
diet (N) with a rat sulphite oxidase probe. A hybridization signal of approximately 
1.8 kb occurred. Probing with β-actin as a control is shown at the lower panel. 





4.3.2 Effect of Molybdenum supplement, sodium sulphite and sodium 
tungstate administration on Sprague Dawley rats 
Previous studies have shown that dietary molybdenum (Yang and Yang, 
1989), sulphite (Gunnison et al, 1981a) and tungstate (Johnson et al, 1974; 
Gunnison et al, 1981b and Renner and Wever, 1983), modulated the activity of 
sulphite oxidase in rats. In view of these, various attempts were carried out to induce 
the desired modulated status of sulphite oxidase activity in rats in order to examine 
the hepatic SUOX gene expression in such instances. The northern blot analysis 
does not indicate an obvious expression pattern (Figures 16, 17 and 18). Sulphite 












Figure 16. Expression of hepatic sulphite oxidase gene in sulphite-treated rats. 
A hybridization signal of approximately 1.8 kb occurred when the Northern 
blot was probed with sulphite oxidase gene. Probing with  β-actin as a 
control which results a band at 2 kb is shown at the lower panel. W10 and 
S2 show degradation of RNA, thereby they are excluded from the data 
analysis. Due to the inherent vulnerable nature of RNA to RNase 

































Figure 17. Expression of hepatic sulphite oxidase gene in tungstate-treated rats.  
A hybridization signal of approximately 1.8 kb occurred when the Northern 
blot was probed with sulphite oxidase gene. Probing with β-actin as a control 
which results a band at 2 kb is shown at the lower panel. T12 (3) shows 
degradation of RNA, thereby it is excluded from the data analysis. Due to the 
inherent vulnerable nature of RNA to RNase degradation, additional proper 























Figure 18. Expression of hepatic sulphite oxidase gene in molybdate-treated 
rats. A hybridization signal of approximately 1.8 kb occurred when the 
Northern blot was probed with sulphite oxidase gene. Probing with β-actin as 
a control which results a band at 2 kb is shown at the lower panel. W10 
shows degradation of RNA, thereby it is excluded from the data analysis. 
Due to the inherent vulnerable nature of RNA to RNase degradation, 























4.3.3 Effect of sodium sulphite and sodium molybdate on HepG2 cell line 
In an attempt to study the effect of sulphite and molybdate ions on the 
expression of SUOX in cell lines, four cell lines, namely, the HepG2, MDCKII, 
Neural 2A cell and human foetal liver cell lines were obtained to detect for their 
SUOX expressions. Preliminary testings have shown that only HepG2 cells are able 
to express SUOX at basal levels (Figure 19).  As a result, HepG2 was selected. After 
exposing HepG2 for 1 and 4 hours, only some signals were barely detectable in 4-
hour molybdate-treated cells and control cells (Figure 20). Also, astonishingly there 













expression. About 20µg of poly A+ RNA of each cell line was loaded and 
hybridised with human SUOX probe. A hybridization signal of approximately 
2 kb, presumably SUOX gene expression, was detectable only in HepG2 
cell. To control RNA loading, the same blot was rehybridised with a GAPDH 














igure 20. Effect of sulphite and molybdate on HepG2 cells.  About 20µg of 






hybridization signal of approximately 1.4 kb was observed in C1 and M1 
lanes. To normalise RNA loading, the blots were rehybridised with β-actin 
and band at around 2 kb is shown at the bottom. There are no detectable 
signals in S1, C4, M4 and S4. C for control, S for sulphite-treated and M for 








5.1 Sulphite oxidase deficiency  
Studies of sulphite oxidase activities in tissues of various animals have been 
carried out using a variety of methods (Gunnison et al, 1977; Tejnorova, 1978; 
Beck-Speier et al, 1985 and Cabre et al, 1990). In various species including humans, 
the liver shows high sulphite oxidase activity. This consistent finding may be 
attributed to the constant need for the oxidation of sulphite generated endogenously 
through the metabolic pathway of cysteine and the “first pass” hepatic portal 
circulation that carries sulphite from its exogenous dietary source and relevant 
metabolites to this organ (Gibson and Strong, 1973 and 1974). With this concept in 
mind, the kidney would be the secondary organ to clear any remaining sulphites 
present in the blood that escape the “first pass” circulation (Oshino and Chance, 
1975) or accumulate during the systemic circulation (Gunnison and Jacobsen, 1987). 
In cardiac and skeletal muscles, rapid amino acid metabolism may contribute to the 
high sulphite oxidase activity. Low-level, long term exposures of sulphur dioxide, an 
ubiquitous air pollutant (WHO, 2000 and Yu, 2001) may likewise contribute to the 
detoxifying capability of the lung despite the fact that it has a very low sulphite 
oxidase activity (Beck-Speier et al, 1985) and that glutathione may play a major role 
in the detoxification of sulphur dioxide (Kagedal et al, 1986 and Mannervik et al, 
1974). 
Isolated sulphite oxidase deficiency case was first described by Mudd et al in 
1967. Since then, the main clinical pictures of sulphite oxidase deficiency are 
progressive neurological deterioration, lens subluxation, intractable spasticity and 
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attenuated growth of brain (Kisker et al, 1997). However, there is no clear 
understanding of the biochemical relationship between sulphite oxidase deficiency 
and the clinical findings. The underlying mechanism of toxicity is speculative. In 
most cases, excessive sulphite and/or sulphate deficiency are the attributing factors 
(Irreverre et al, 1967; Johnson and Wadman, 1995 and Lyon et al, 1996). Previous 
studies have shown that sulphites are able to induce the generation of oxygen and 
sulphur radicals (Shi, 1994) which in turn damage disulphide bonds (Cecil, 1963), 
nucleic acids (Hayatsu and Miller, 1972; Shi and Mao, 1994), membrane lipids and 
proteins (Pryor 1971), as well as impair mitochondrial function directly via the 
disruption of membrane integrity or indirectly by interfering with thiamine in the 
Kreb cycle of the cellular compartments of central nervous system (Arslanoglu et al, 
2001). In addition, an increase in taurine (an inhibitory neurotransmitter), 
thiosulphate and S-sulphocysteine may be harmful to the developing brain (Olney et 
al, 1975). S-sulphocysteine is produced by the non-enzymatic reaction of 
accumulated sulphites with cysteine while thiosulphate is generated from β-
mercaptopyruvic acid and sulphite (Figure 2). It has been suggested that as S-
sulphocysteine is structurally very similar to glutamate and other excitotoxic amino 
acids, it therefore shares their toxic properties (Olney and Ho, 1970).  A synergistic 
toxic effect of sulphites with the peroxynitrites produced during hypoxic stress or 
neurodegenerative diseases may also be implicated (Reist et al, 1998). Similarly, the 
reaction of sulphites with nitric oxide, a neurotransmitter and its carriers may also 
play a part in sulphite toxicity (Harvey and Nelsestuen, 1995). Alternatively, 
sulphate deficiency may also be involved in the pathogenesis given that sulphatides 
are organic sulphate esters present in myelin and their synthesis in neural tissue 
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require organic sulphate. Yet, Percy et al (1968) reported that neither qualitative nor 
quantitative deficiency of sulphatides was observed in one patient and van der Klei-
van Moorsel et al (1991) noted the normal excretion of sulphates in urine. As such, 
the likelihood of sulphate deficiency in the pathogenesis of sulphite oxidase 
deficiency is implausible. Of interest, a recent study has reported that neuronal 
cytotoxicity could be the result of N-methyl D-aspartate receptor activation (Olney 
et al, 1975) arising from the excessive accumulation of magnesium in neurons 
(Salman et al, 2002). With the inhibition of N-methyl D-aspartate receptor by 
dextrometorphan ameliorating the clinical neurological pictures in sulphite oxidase 
deficient patients, this mode of pathogenesis certainly requires more elucidations 
(Kurlemann et al, 1996). 
Lens subluxation is one of the clinical ophthalmologic hallmarks of sulphite 
oxidase deficiency, although other conditions such as molybdenum cofactor 
deficiency, homocystinuria and Marfan’s syndrome may also be implicated. The 
etiology for such finding has been postulated by Parini et al (1997) to be an 
abnormal relaxation of zonular fibers that are rich in fibrillin. As S-sulphocysteine is 
high in sulphite deficiency subjects, the disruption of cysteine disulphide bonds by 
sulphite and replacement of S-sulphocysteine in the zonule, which is rich in cysteine 
(Streeten, 1982), causes spherophakia to occur. As a result, lens dislocation ensues. 
 
5.2 Distribution of sulphite oxidase activity 
Tissue extracts of liver, kidney, heart and intestine were assayed for sulphite 
oxidase activity using cytochrome c reduction methodology. The occurrence of 
sulphite oxidase activity in these tissues was found to be in the decreasing order of 
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liver > kidney > heart > intestine. This observation is consistent with the previous 
studies of sulphite oxidase activity (Gunnison et al, 1977; Tejnorova, 1978; Beck-
Speier et al, 1985 and Cabre et al, 1990). 
 
5.3 Differential expression profiles 
In the present study, the expression of sulphite oxidase gene in the human 
and rat was investigated and the expression profiles were found to generally 
correlate with the previous studies of activity (Gunnison et al, 1977; Tejnorova, 
1978; Beck-Speier et al, 1985 and Cabre et al, 1990). A general trend noted in this 
study was a higher expression level of sulphite oxidase gene in the liver followed by 
a substantial expression in the kidney. This expression pattern, as discussed earlier, 
may be the result of its physiological needs. Interestingly, there was no detectable 
expression in the rat skeletal muscle. Therefore, this finding could possibly explain 
the undetectable sulphite oxidase activity at this anatomical site (Kessler et al, 
1974).  
In the brain, all areas examined shared some expression of the sulphite 
oxidase gene. The higher expression in the cerebral cortex on the human brain 
MTN™ blots (Figure 13) suggests that this brain region may require higher enzyme 
levels, perhaps due to greater formation of SO
2-
3  during metabolism. This hypothesis 
is consistent with the clinical evidence of neurodestruction in the cortex as seen on 
computed tomography (CT) and Magnetic Resonance Imaging (MRI) findings of 
various sulphite oxidase deficient patients (Brown et al, 1989; Barbot et al, 1995; 
Schuierer et al, 1995; Rupar et al, 1996; Goh and Lim, 1997; Hughes et al, 1998; 
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Edwards et al, 1999; Arslanoglu et al, 2001; Topcu et al, 2001; Dublin et al, 2002 
and Salman et al, 2002). 
In conclusion, the differential expression of sulphite oxidase gene correlates 
with numerous previous studies of activity (Kessler et al, 1974; Gunnison et al, 
1977; Tejnorova, 1978; Beck-Speier et al, 1985 and Cabre et al, 1990). Such 
correlation may imply that the sulphite oxidase gene is under transcriptional 
regulation. To investigate this hypothesis, various in vitro and in vivo experiments 
were carried out.  
 
5.4 Animal studies 
Initial evidence for the induction of sulphite oxidase activity was obtained 
from an in vivo study done by Amy (1988) who demonstrated a significant increase 
in the hepatic sulphite oxidase activity of Sprague Dawley rats after two weeks of 
high casein diet. As such, a similar experiment was set up in the first approach to 
assess the extent of sulphite oxidase gene induction. Consistent with the study, the 
hepatic sulphite oxidase activity was found to be generally higher in those rats 
subjected to a high casein diet, attaining approximately a twofold increase (Table 9). 
However, such a significant increment was not indicated in all of the northern blot 
analyses as only kidney RNA and liver poly A+ RNA showed greater expression of 
sulphite oxidase gene in varying extents in rats fed with high casein diet  (Figure 
15B and C). With this doubt, additional investigations were initiated. 
Previous studies conducted on rodent models showed that dietary 
molybdenum (Yang and Yang, 1989), sulphite (Gunnison et al, 1981a) and tungstate 
(Johnson et al, 1974; Gunnison et al, 1981b and Renner and Wever 1983) could 
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modulate the activity of sulphite oxidase in rats. To date, the mechanism underlying 
this modulation is presumably to be the inability of molybdenum incorporation into 
the active site of sulphite oxidase (Johnson et al, 1977). As a result of these 
attention-grabbing findings, various attempts were carried out to induce the desired 
modulated status of sulphite oxidase activity in rats in order to examine the exact 
status of hepatic SUOX gene expression. It is apparent that one would predict the 
expression of sulphite oxidase gene to be greater in tungstate-treated rats (T5 and 
T12) as their synthesis of sulphite oxidase is reduced (Johnson et al, 1974; Gunnison 
et al, 1981b and Renner and Wever, 1983). To meet the physiological demand for 
the detoxification of sulphite derived from normal intake of proteins at reduced 
levels of sulphite oxidase, induction of sulphite oxidase gene should ensue. Yet, 
Northern blot analyses failed to produce such evidence significantly. Only rats on T5 
regimen were able to show an increase in sulphite oxidase gene expression. One 
possible reason for the failure of T12 regimen to induce gene expression may be that 
heightened tungstate administration of 12 000ppm in the last 4 weeks collapses the 
normal gene induction machinery. Similarly, when intake of sulphite or molybdate is 
increased (the S and M regimens), induction of sulphite oxidase gene should ensue 
because sulphite and molybdate are presumably acting as inducers of gene 
expression in this context. On the contrary, no distinctive expression patterns were 
noted on Northern blotting (Figure 17 and 18). Although induction of hepatic 
sulphite oxidase activity could not be demonstrated in this study nor in rats treated 
with a single dose of 200 mg SO2/kg or given 50 or 200 mg of SO2/kg/day for 30 
days (Gibson and Strong, 1973), it is not clear whether there exists a critical 
concentration for induction or that induction by sulphite is simply unattainable. 
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However, it should not be neglected that the higher level of SUOX gene expression 
in T5 regimen might be due, at least in some part, to the effects of sulphur-
containing amino acids in the normal diet. As the sulphite oxidase activity of all 
treated rats (the treatment regimens of S, T5, T12 and M) could not be satisfactorily 
examined due to the differential dietary habits of the rats and also because of an 
inadvertent overnight thawing of all collected tissues arising from a power failure, 
the sulphite oxidase status of each regimen remains inconclusive.  
To further examine the effect of sulphite, tungstate and molybdate on the 
expression of SUOX gene in rats, future reports on Northern analysis and sulphite 
oxidase activity of individual treatment and control rat is essential. Statistically, this 
is to facilitate a pair-wise comparison. In addition, storage conditions must be 
carefully maintained to minimise samples deterioration. Certainly, optimization of 
the critical concentration of each chemical used has to be carried out.  
 
5.5 Cell culture studies 
In a model system using HepG2 cells to examine the ability of sulphite and 
molybdate in modulating the expression of sulphite oxidase gene, no specific 
expression patterns were obtained. While a hybridization signal was observed on 
northern blotting for the 1-hour molybdate-treated cell and control cells but not for 
the sulphite-treated cells (Figure 20), its molecular size of 1.4 kb somewhat does not 
suggest the detection of a genuine sulphite oxidase gene. Intriguingly, a SUOX-like 
pseudogene or an allelic form of sulphite oxidase gene could possibly be present in 
the transformed cells. However, the present data is not conclusive. 
 52
As mentioned previously, sulphite oxidase is expressed in fibroblasts, 
cultured amniotic fluid cells and lymphoblasts (Johnson and Wadman, 1995). As 
such, human fibroblast and lymphoblast cell lines, which are commercially 
available, should be utilised to investigate the regulatory mechanisms of SUOX gene 
expression in future. Alternatively, primary intact parenchymal rat liver cells are a 
good source of non-transformed cells. They can be prepared using collagenase 
perfusion technique, which is a technically challenging task. Likewise, the 
establishment of mass cultures of nongrowing adult parenchymal rat liver cells is 
difficult. Nevertheless, despite of all these technical aspects, these approaches may 
serve to represent a closer state of their counterparts in vivo. Due to limited 
resources and restricted financial funding, only four cell lines were obtained in this 
study. Notably, only two of the four cell lines, namely, HepG2 and human foetal 
liver cells were from human. As a result, the lack of expression of sulphite oxidase 
in MDCKII (canine) and Neural 2A cells (mouse) was due to the inadvertent use of 
inappropriate probe (human SUOX probe) (Figure 19).  
 
5.6 Future studies 
In view of the available data generated from this study, it is clear that the 
underlying mechanism of gene expression is still very far from completion. 
Although sulphite oxidase activity can be induced following a high casein diet, the 
physiological basis underlying this phenomenon remains an enigma.  
Even though the current findings are of no breakthrough value, these may 
serve as a preliminary study for future works. Further characterization of the 
regulatory elements of the SUOX gene can only be feasible if the gene could be 
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induced substantially in vivo or in vitro. By gaining a better insight into the 
regulatory mechanisms and knowing the promoter and enhancer sites of the SUOX 




In summary, the expression of sulphite oxidase gene in human brain and in 
other human and rat tissues was elucidated. The presence of sulphite oxidase in 
these anatomical sites offers a protective role in detoxifying sulphite and the low 
levels of expression of this enzyme may predispose the brain to damage by excess 
sulphite (SO
2-
3  ). A deficiency of sulphite oxidase inevitably leads to severe and 
progressive neurological degeneration and death at an early age.  
As yet, no substantial studies have been conducted to assess the regulation of 
sulphite oxidase gene expression. Given the current limitations of therapeutic 
intervention to treat sulphite oxidase-deficient patients, more extensive studies are 
therefore needed to provide insights into a rational approach to this devastating 
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Sulphite oxidase (EC 1.8.3.1) is a molybdopterin-containing enzyme that catalyses the oxidation of 
sulphite to sulphate. Lack of active enzyme produces severe neurodegeneration and early death in 
humans, showing its essential role. Despite this, the expression of the sulphite oxidase gene in 
human and rat tissues (especially the brain) has not been elucidated. We therefore examined these 
tissues and found that the human liver, kidney, skeletal muscle, heart, placenta and brain showed 
substantial expression while thymus, spleen, peripheral blood leucocytes, colon, small intestine and 
lung showed little expression in humans. In rat, the liver, kidney, heart, brain and lung (but not 
skeletal muscle) revealed a hybridization signal with the strongest signal in the liver. The spleen 
and testis also showed little expression. The differential expression of sulphite oxidase gene in 
various human brain regions was studied. Expression was seen in all brain regions examined 
(cerebellum, cerebral cortex, medulla, spinal cord, occipital pole, frontal lobe, amygdala, caudate 
nucleus, corpus callosum, hippocampus, thalamus, temporal lobe and putamen). The cerebral 
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Sulphite oxidase (EC 1.8.3.1), located in the mitochondrial intermembrane space, is a molybdopterin-
containing enzyme that catalyses the oxidation of sulphite to sulphate. It catalyses the terminal step in 
the oxidative degradation of sulphur-containing amino acids. Sulphite toxicity is implicated in the 
premature death of SO-deficient infants as a result of severe neurologic deterioration. In the present 
study, the expression of sulphite oxidase gene in human and rat was investigated using Northern blot 
analysis. In human, tissues including the liver, kidney, skeletal muscle, heart, placenta, brain, thymus 
and spleen showed substantial expression while peripheral blood leucocyte, colon, small intestine and 
lung showed little expression.  In rat, the liver, kidney, heart, brain and lung revealed a hybridization 
signal with the strongest signal been noted in the liver. The spleen, testis and skeletal muscle showed 
little expression. Increased expression in the liver coincides with high sulphite oxidase activity in this 
organ. Briefly, the expression profiles generally correspond to the previous enzyme activity studies. 
The differential expression of sulphite oxidase gene in various human brain regions was studied. A 
decreasing expression pattern was found in the order of putamen > temporal lobe > cerebral cortex > 
frontal lobe > occipital pole > spinal cord > medulla > cerebellum. Likewise, a similar pattern like 
caudate nucleus > amygdala> hippocampus> brain (whole)> corpus callosum> thalamus was 
obtained using a different blot.  
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